Show simple item record

dc.contributor.authorEvens, Andrew
dc.contributor.authorHong, Fangxin
dc.contributor.authorGordon, Leo I.
dc.contributor.authorFisher, Richard I.
dc.contributor.authorBartlett, Nancy L.
dc.contributor.authorConnors, Joseph M.
dc.contributor.authorGascoyne, Randy D.
dc.contributor.authorWagner, Henry
dc.contributor.authorGospodarowicz, Mary
dc.contributor.authorCheson, Bruce D.
dc.contributor.authorStiff, Patrick J.
dc.contributor.authorAdvani, Ranjana
dc.contributor.authorMiller, Thomas P.
dc.contributor.authorHoppe, Richard T.
dc.contributor.authorKahl, Brad S.
dc.contributor.authorHorning, Sandra J.
dc.date2022-08-11T08:08:19.000
dc.date.accessioned2022-08-23T15:51:04Z
dc.date.available2022-08-23T15:51:04Z
dc.date.issued2013-04-01
dc.date.submitted2013-07-02
dc.identifier.citationBr J Haematol. 2013 Apr;161(1):76-86. doi: 10.1111/bjh.12222. Epub 2013 Jan 29. <a href="http://dx.doi.org/10.1111/bjh.12222">Link to article on publisher's site</a>
dc.identifier.issn0007-1048 (Linking)
dc.identifier.doi10.1111/bjh.12222
dc.identifier.pmid23356491
dc.identifier.urihttp://hdl.handle.net/20.500.14038/28810
dc.description.abstractThere is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) and Stanford V (SV; doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone) regimens in older Hodgkin lymphoma (HL) patients. Forty-four advanced-stage, older HL patients (aged >/=60 years) were treated on the randomized study, E2496. Toxicities were mostly similar between chemotherapy regimens, although 24% of older patients developed bleomycin lung toxicity (BLT), which occurred mainly with ABVD (91%). Further, the BLT-related mortality rate was 18%. The overall treatment-related mortality for older HL patients was 9% vs. 0.3% for patients aged (P < 0.001). Among older patients, there were no survival differences between ABVD and SV. According to age, outcomes were significantly inferior for older versus younger patients (5-year failure-free survival: 48% vs. 74%, respectively, P = 0.002; 5-year overall survival: 58% and 90%, respectively, P < 0.0001), although time-to-progression (TTP) was not significantly different (5-year TTP: 68% vs. 78%, respectively, P = 0.37). Furthermore, considering progression and death without progression as competing risks, the risk of progression was not different between older and younger HL patients (5 years: 30% and 23%, respectively, P = 0.30); however, the incidence of death without progression was significantly increased for older HL patients (22% vs. 9%, respectively, P < 0.0001). Altogether, the marked HL age-dependent survival differences appeared attributable primarily to non-HL events.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23356491&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1111/bjh.12222
dc.subjectAge Factors
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjecteffects
dc.subjectBleomycin
dc.subjectDacarbazine
dc.subjectDoxorubicin
dc.subjectEtoposide
dc.subjectFemale
dc.subjectHematologic Diseases
dc.subjectHodgkin Disease
dc.subjectHumans
dc.subjectLung Diseases
dc.subjectMale
dc.subjectMechlorethamine
dc.subjectMiddle Aged
dc.subjectNeoplasm Staging
dc.subjectPrednisone
dc.subjectSurvival Analysis
dc.subjectTreatment Outcome
dc.subjectVinblastine
dc.subjectVincristine
dc.subjectClinical Epidemiology
dc.subjectHematology
dc.subjectHemic and Lymphatic Diseases
dc.subjectOncology
dc.titleThe efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
dc.typeJournal Article
dc.source.journaltitleBritish journal of haematology
dc.source.volume161
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/105
dc.identifier.contextkey4276321
html.description.abstract<p>There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) and Stanford V (SV; doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone) regimens in older Hodgkin lymphoma (HL) patients. Forty-four advanced-stage, older HL patients (aged >/=60 years) were treated on the randomized study, E2496. Toxicities were mostly similar between chemotherapy regimens, although 24% of older patients developed bleomycin lung toxicity (BLT), which occurred mainly with ABVD (91%). Further, the BLT-related mortality rate was 18%. The overall treatment-related mortality for older HL patients was 9% vs. 0.3% for patients aged (P < 0.001). Among older patients, there were no survival differences between ABVD and SV. According to age, outcomes were significantly inferior for older versus younger patients (5-year failure-free survival: 48% vs. 74%, respectively, P = 0.002; 5-year overall survival: 58% and 90%, respectively, P < 0.0001), although time-to-progression (TTP) was not significantly different (5-year TTP: 68% vs. 78%, respectively, P = 0.37). Furthermore, considering progression and death without progression as competing risks, the risk of progression was not different between older and younger HL patients (5 years: 30% and 23%, respectively, P = 0.30); however, the incidence of death without progression was significantly increased for older HL patients (22% vs. 9%, respectively, P < 0.0001). Altogether, the marked HL age-dependent survival differences appeared attributable primarily to non-HL events.</p>
dc.identifier.submissionpathfaculty_pubs/105
dc.contributor.departmentDepartment of Medicine, Division of Hematology/Oncology
dc.source.pages76-86


This item appears in the following Collection(s)

Show simple item record